BRAF and non-small cell lung carcinoma: Activating mutations in BRAF have been described in MM ( ̃50%), thyroid (THCA, 30–50%), colorectal (CRC, 10%), non-small cell lung (NSCLC, 3%) cancers and in hairy cell leukemia (HCL, 100%) [12].